Spore in skin cancer

Active Project Grant Awarded Last action

Award ID
P50CA261608
Recipient
Awarding agency
Obligated
$27,278,939

Award facts

Assistance listing
93.397 Cancer Centers Support Grants
Completion date 97% complete
Originally
Funding
  • $24,955,027.00 Federal
  • $2,323,912.00 Non-federal
Place of performance
Philadelphia, PA 19104, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Overall this wistar/upenn skin spore represents a highly successful and longstanding collaboration. Immune checkpoint inhibition has revolutionized melanoma therapy to the point where every high-risk melanoma patient will be treated at some point with these agents. However, many major questions remain on how best to use these immune therapeutics. Project 1 will address the unmet need to find an effective biomarker to select patients for single agent versus combination immunotherapy. Many patients start treatment with ipilimumab and nivolumab, when they may have responded to anti-PD-1 antibody (AB) alone, exposing these patients unnecessarily to the toxicity of combination checkpoint inhibition. Project 1 builds on a fundamental discovery made through our developmental research program (DRP) that exosomal PD-L1 is an immunosuppressive factor secreted by melanomas. We propose rigorous clinical utility studies designed to demonstrate this blood- based measurement as a highly sensitive and specific predictive biomarker for anti-PD-1 antibody (AB)-based therapy. Project 2 will address a second unmet need for a safer and effective combination regimen that promises to be effective in anti-PD-1 AB refractory patients. Based on extensive preclinical data and a new molecular target in the autophagy pathway, we have developed a clinical trial of combined anti-PD1 AB and autophagy inhibition, a new strategy for reprogramming tumor-associated macrophages to enhance the efficacy of T cell killing. Project 3 fills a major GAP in the treatment of early disease by conducting a clinical trial with anti-PD1 AB in stage IIB/C melanoma patients. Besides in-depth characterization of the immune response, the project's preclinical studies will lead to new strategies for enhancing the immune stimulatory capacity of dendritic cells in the tumor microenvironment. These three highly translational projects are supported by longstanding cores that have a proven track record of adapting to the rapidly changing needs of melanoma and non-melanoma skin cancer researchers. Each project was chosen by the current spore leadership for its potential for significance, impact and innovation. Together, they have the potential to advance therapeutically exploitable biological insights into new, clinically important therapies of patients with melanoma. Funding from the spore has provided US with important advantages, including a mature, collective, translational mindset, an efficiently functioning tumor bank, and a highly evolved framework of collaboration between the wistar institute and upenn. The spore has allowed US to bolster horizontal and vertical collaborations with academic and industry partners throughout the world. The career enhancement program and DRP have enabled transition to new leadership, have formed the three projects proposed, and have allowed our research to reach into other cancers of the skin including SCC, ctcl and merkel cell carcinoma. These programs will continue to be supported robustly by strong institutional support from both wistar and upenn. Funding of this spore will bring new advances from the bench to the bedside and fulfill our overall mission of improving survival for skin cancer patients.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $2,351,294 $0
Amendment $2,351,294 $0
Amendment $0 $0
Amendment $0 $0
Amendment $2,257,242 $0
Amendment $2,257,242 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $2,186,705 $0
Amendment $2,186,705 $0
Amendment $2,186,705 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $47,186 $0
Amendment $47,186 $0
Amendment $47,186 $0
Amendment $47,186 $0
Amendment $47,186 $0
Amendment $2,147,043 $0
Amendment $2,147,043 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $2,323,912 $0
Original award $2,323,912 $2,323,912
Show all 34

Subawards

Subrecipient Amount Awarded
The Trustees Of The University Of Pennsylvania We established the infrastructure to collect blood, tumor, and TIL product from melanoma patients receiving the FDA-approved TIL therapy lifileucel. We will… $81,250
The Trustees Of The University Of Pennsylvania As co-Leader of the Administrative Core, Dr. Amaravadi will work alongside Dr. Herlyn providing overall scientific and administrative leadership of the SPORE.… $62,699
The Trustees Of The University Of Pennsylvania The primary objective of the Biospecimen and Pathology Core (Core B) of the Wistar/UPenn Skin Cancer SPORE is to procure, process, distribute, and analyze… $304,154
The Trustees Of The University Of Pennsylvania This project will now focus on in vivo and clinical investigations using next generation chemical lysosomal and non-lysosomal autophagy inhibitors that are… $224,114
The Trustees Of The University Of Pennsylvania The overarching goals of Project 1 are to develop a quantitative liquid biopsy-based tool that enables clinicians to predict the patient response to ICl-based… $427,269
The Trustees Of The University Of Pennsylvania This Project investigates the role of neoadjuvant immunotherapy and the SLN in melanoma as determinants of clinical outcomes in early-stage disease. Studies… $256,130
The Trustees Of The University Of Pennsylvania I Core C staff will continue providing biostatistics and bioinformatics expertise to SPORE investigators including data management, design of experimental and… $160,084
The Trustees Of The University Of Pennsylvania The overarching goals of Project 1 are to develop a quantitative liquid biopsy-based tool that enables clinicians to predict the patient response to ICI-based… $1,593,999
The Trustees Of The University Of Pennsylvania The primary objective of the Biospecimen and Pathology Core of the Wistar/UPenn SPORE in Skin Cancer is to provide a centralized facility focused on… $1,138,226
The Trustees Of The University Of Pennsylvania The Biostatistics and Bioinformatics Core key personnel will provide expertise and experience in five key areas. The first is to provide a robust… $599,068
The Trustees Of The University Of Pennsylvania In Aim 1, Drs. Karakousis (Clinical co-Project Leader (PL)) and Schuchter (co-Investigator (I)) will conduct an investigator-initiated Phase II clinical trial… $958,505
The Trustees Of The University Of Pennsylvania A new approach that can overcome resistance to immune checkpoint inhibition (ICI) is a major unmet need for Stage IV melanoma patients. The overall goal of this… $838,695
Saint John's Cancer Institute The SOS will be to provide blood (Plasma or serum) or melanoma patients checkpoint inhibitor immunotherapy (CII) from JWCI clinic at SJHC. Melanoma patients… $60,459
The Trustees Of The University Of Pennsylvania As Co-leader of the Administrative Core. Dr. Amaravadi will work alongside Dr. herlyn providing overall scientific and administrative leadership of the SPORE.… $230,376
Show all 14

Quick answers

Who received award P50CA261608?

P50CA261608 was awarded to The Wistar Institute Of Anatomy And Biology by National Cancer Institute (National Institutes of Health) on September 3, 2021.

How much is award P50CA261608 worth?

$27,278,939 has been obligated on P50CA261608: $24,955,027 in federal funding and $2,323,912 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login